Ninety-one thousand women. That is the number a 2013 analysis estimated died prematurely between 2002 and 2012 from conditions that hormone replacement therapy might have helped prevent. Let that number sit next to the wellness industry's obsession with "natural" approaches to menopause. Ninety-one thousand is not abstract. It is the direct, measurable cost of bad science communication masquerading as caution.
In November 2025, the FDA and HHS announced the removal of broad black-box warnings from HRT products for menopause. The FDA initiated this removal following a comprehensive review of the scientific literature, an expert panel in July, and a public comment period. The labels had stood for over two decades, and HRT use had plummeted in the early 2000s when the FDA applied those boxed warnings following a Women's Health Initiative study that found a statistically non-significant increase in the risk of breast cancer diagnosis. Non-significant. That word matters.
What the 2002 Study Actually Said, and What We Were Told
Here is what the research actually says about the WHI study: it was not designed to answer the question most women and doctors thought it answered. The average age of women in the study was 63 years, over a decade past the average age of a woman experiencing menopause, and study participants were given a hormone formulation no longer in common use. Researchers then applied findings from a 63-year-old cohort to a 51-year-old newly menopausal woman. That is not science. That is a category error with a press release.
Use of HRT plummeted by as much as 80% after the media picked up the narrative that it causes breast cancer and heart disease. Before the WHI, HRT initiation was at 8.6%, but it dropped to 2.8% following the WHI and then to 1.9% two years later. The researchers most closely involved knew the messaging had gone off the rails. The study results were not statistically significant for breast cancer harm. In fact, the only significant findings were an increase in venous blood clots and a reduction in hip fractures. Neither of those facts made the headline.
And then the results from the WHI report, which focused on treating an older, asymptomatic group, were falsely generalized over the past 21 years to include all estrogen products, all ages of menopausal women, and all methods of delivery. I want to be precise about how furious this should make you. A study that enrolled women averaging age 63 was used to scare women in their early 50s away from treatment. The epidemiological damage was immediate and lasting.
What the Evidence Actually Supports in 2026
The good news: we now have a much clearer picture. Timing is the central variable, and it has been for years. Randomized studies cited by the FDA support favorable outcomes when HRT is started within 10 years of perimenopause, generally before age 60, including reductions in all-cause mortality and fractures. Two meta-analyses pooling data from 23 and 30 randomized clinical trials, respectively, reported a decrease in CVD and all-cause mortality in HRT users younger than 60 years of age or in those who began menopause less than 10 years prior. That is not one flashy study. That is cumulative evidence.
A large retrospective cohort analysis based on data from more than 120 million patient records, presented at the 2025 Annual Meeting of the Menopause Society, found that perimenopausal women who used estrogen within 10 years prior to menopause had no significantly higher associated rates of breast cancer, heart attack, and stroke compared to the other groups. The effect size on benefit is moderate to meaningful. The risk window, when therapy is initiated correctly, is genuinely small for healthy women under 60.
Formulation matters as much as timing. Transdermal estrogen avoids hepatic metabolism and is considered safer for women at increased risk of thromboembolic or cardiovascular events. A 2025 narrative review in the International Journal of Molecular Sciences found that hormonal therapies effectively reduce vasomotor symptoms by 70 to 90 percent and preserve bone density, with low-dose transdermal regimens minimizing VTE and breast cancer risks per NAMS and IMS guidelines. The choice of progestogen also matters: norethisterone-estradiol was associated with the highest breast cancer risk rises, while dydrogesterone-estradiol carried the lowest risk rise among combination therapies.
I want to be clear about what the evidence does not say. It does not say HRT is risk-free. Systemic therapy may cause transient breast tenderness, bloating, or irregular bleeding, and carries uncommon risks such as venous thromboembolism, gallbladder disease, or, with certain formulations, increased breast cancer risk. A Finnish nationwide cohort study published in the European Journal of Cancer in 2025, tracking 357,928 MHT users from 1994 to 2019, confirmed that menopausal hormone therapy-related breast cancer risks remain unchanged, and all systemic regimens were accompanied with elevated breast cancer risk. The magnitude varies by formulation and duration; it does not vanish. What changed is our understanding of how to minimize that risk, not whether it exists.
These risks are typically small in healthy women under 60 and can be minimized through individualized treatment planning and regular follow-up. That sentence should be the entire policy framework. Not blanket warnings. Not blanket enthusiasm. Individual risk assessment by a clinician who knows the current literature.
The Right Call, for the Wrong Reasons, Delivered Imperfectly
The FDA's label change was the correct regulatory action. The evidence base for it is solid, and the 2002 warnings were applied to products and populations they were never tested on. That part is defensible.
What concerns me is how this is being communicated. The removal of a black-box warning will be received by many patients as "HRT is safe." That is not what the evidence says. The evidence says: HRT is safe for specific candidates, using specific formulations, initiated within a specific window, under clinical supervision. Those words are not interchangeable with a social media post declaring the "hormone era" is back.
The observational study design is subject to known potential biases such as healthy user bias. The breast cancer risk data from large European cohorts still show elevated signals with longer duration of use. The International Menopause Society believes the decline in HRT use "has disadvantaged nearly a decade of women who may have unnecessarily suffered severe menopausal symptoms and who may have missed the potential therapeutic window to reduce their future cardiovascular, fracture, and dementia risk." That is a real cost. So is communicating this policy shift as simpler than it is.
The fundamentals of evidence-based medicine do not change because a regulatory agency finally caught up with the literature. Thirty million women enter menopause every year in the United States. They deserve a conversation about timing, formulation, personal risk profile, and realistic effect sizes. Not a headline. Show them the study.
